Epigenetic reader domain antagonists are emerging as critical players in the field of epigenetics. These compounds target reader proteins that interpret epigenetic marks on DNA, influencing gene expression. By inhibiting these readers, it becomes possible to modulate gene activity, which holds great promise in treating various diseases, especially cancer and genetic disorders.
